tiprankstipranks
Iovance Biotherapeutics price target raised to $17 from $16 at Truist
The Fly

Iovance Biotherapeutics price target raised to $17 from $16 at Truist

Truist analyst Asthika Goonewardene raised the firm’s price target on Iovance Biotherapeutics to $17 from $16 and keeps a Buy rating on the shares. The company’s acquisition of Proleukin is viewed positively as it allows Iovance to secure the supply chain, while providing only incremental sales potential, the analyst tells investors in a research note. Truist is also "encouraged" by the company’s data for lifileucel in PD-1 naive mNSCLC as disclosed in Iovance’s update, though it adds that the durability of response still needs to be established.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on IOVA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles